WHIM – Warts, Hypogammaglobulinemia, Infections and Myelokathexis

WHIM – Warts, Hypogammaglobulinemia, Infections and Myelokathexis

About this clinical trial

This is a multicentre, randomised, double-blind, placebo-controlled Phase III study to investigate the efficacy and safety of for the treatment of Mavorixafor in patients with Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM).

Patients Required

Estimated completion

Follow-up completed 2022

Total participants required

Closed for recruitment

Study location

The Wesley Hospital

Trial title

A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of in Patients with WHIM Syndrome with Open-Label Extension (4WHIM) 


Inclusion criteria:

  1. Be at least 12 years of age.
  2. Have a genotype-confirmed mutation of CXCR4 consistent with WHIM phenotype.
  3. Have a confirmed ANC ≤400 cells/µL during screening, obtained while patient has no clinical evidence of infection. 

Additional information

You can find out more about the WHIM trial by visiting the ClinicalTrials.gov website.

Lead investigator

Dr Daman Langguth

If you would like more information about this clinical trial, please complete the WHIM contact form


Wesley Medical Research

Scroll to Top